Power3 Medical Provides Update of Breast Cancer Detection Studies

THE WOODLANDS, Texas, March 10, 2005 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company, announces progress made on the Company's clinical validation studies for the early detection of breast cancer. To date, the multi-site clinical study has enrolled 83 participants from three participating locations, the Clinical Research Center of Houston, Obstetrical and Gynecological Associates (OGA), Mercy Women's Center in Oklahoma City and NYU Medical Center.

The Validation Study involves the collection of nipple aspirate fluid (NAF) and blood serum samples from several hundred women. The collection of the nipple aspirate fluid is a non-invasive procedure utilizing a modified breast pump to obtain a drop of fluid from the nipple. Participants have the NAF fluid and blood serum collected at the clinical sites to be shipped to Power3 for analysis using proprietary technologies which monitor a select group of breast cancer related protein biomarkers.

Previous studies conducted by Power3 Medical using proteomic analysis of this fluid has identified differences in the protein patterns of women with breast cancer, women of high risk for the disease, and normal women with no diagnosed breast cancer. The Company believes that these specific protein profiles can be used to determine if a woman has a normal proteomic pattern or one suggestive of cancer or benign disease.

According to Dr. Ira Goldknopf, Chief Scientific Officer, "Early detection of breast cancer is critical and our technology holds great promise as an earlier and more accurate detection mechanism for the disease. Identified protein biomarkers can not only potentially provide early indications of breast cancer, but may also suggest mechanisms for how the disease develops, with the potential to provide early intervention as well as therapeutic and preventative strategies."

The NAF Test analyzes fourteen biomarkers that together appear to provide a highly sensitive and specific indication of breast cancer. Power3 Medical believes that the Company has engineered the first test of its type that detects breast cancer more effectively and earlier than current technology. The Company has recently filed applications with the United States Patent and Trademark Office for the NAF Test and its constituent biomarkers. Power3 Medical Products continues to make progress towards the validation of the NAF test and to expand its intellectual property and biomarker portfolio.

About Power3 Medical Products, Inc.

Power3 Medical Products, www.Power3Medical.com, is a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. The Company's patent pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The Company's identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.

Safe Harbor Statement

All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.


Contact Data